Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in ...

Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated ...

Independent Data Monitoring Committee recommends ASPIRE continue without modification; no safety concerns identified. Fully ...

Four vulnerabilities in a widely used open-source healthcare interoperability software could enable attackers to improperly ...

Odyssey Therapeutics reports positive Phase 2a results for OD-001 in ulcerative colitis, indicating significant clinical efficacy and safety.

A new study finds that use of the OpenEvidence platform has soared since 2024, with early-career clinicians relying on it ...

The global clinical trial management services market is projected to grow from $36.2 billion in 2025 to $68.4 billion by 2033, a new Research and Markets report finds, with North America holding 34.7% ...

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with ...

The treatment continued to demonstrate a favorable safety profile. Most treatment-related adverse events were Grade 1 or Grade 2 and consisted of localized bladder symptoms associated with ...

Clinical trials are crucial for evidence generation on medicines. As of June, 2025, the European Union’s (EU) clinical trial ...

Health plans rely on clinical data to improve quality, manage risk, coordinate care, and support analytics and AI. But that data arrives from multiple ...

IgniteData, a leader in intelligent clinical trial data automation, and RealTime eClinical Solutions, a leader in clinical research software solutions, today announced a new partnership which will ...